CN102000117A - Use of nutgall extract in preparing medicine for inhibiting cell proliferation of colon cancer - Google Patents
Use of nutgall extract in preparing medicine for inhibiting cell proliferation of colon cancer Download PDFInfo
- Publication number
- CN102000117A CN102000117A CN2010105680272A CN201010568027A CN102000117A CN 102000117 A CN102000117 A CN 102000117A CN 2010105680272 A CN2010105680272 A CN 2010105680272A CN 201010568027 A CN201010568027 A CN 201010568027A CN 102000117 A CN102000117 A CN 102000117A
- Authority
- CN
- China
- Prior art keywords
- cell
- colon cancer
- galla
- extract
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to use of a nutgall extract in preparing a medicine for inhibiting cell proliferation of colon cancer. In the invention, by adopting experimental methods such as methyl thiazolyl tetrazolium (MTT), flow cytometry and the like, a human colon cancer HT-29 cell is taken as an experimental carrier, and functional characteristics of the nutgall extract on the human colon cancer HT-29 cell are described in the aspects of proliferation and apoptosis of cancer cells; and by means of cell proliferation inhibition and cell apoptosis induction, the growth of the colon cancer cells is inhibited, which has a concentration-effect dependence relation. In the use of the invention, an anti-colon cancer action site (that is, a new target point) of the nutgall extract in a molecular biology level is disclosed and a novel natural medicine for prevention and treatment of colon cancer is provided.
Description
Technical field
The present invention relates to the purposes of a kind of Galla halepensis extract in the medicine of preparation inhibition colon cancer cell propagation.
Background technology
Uighur medicine is that uighur ' s culture is in long-term life, produce and with the experience and the crystallization of wisdom that accumulate in the disease struggle, it is an important component part of motherland's medicine, no matter aspect rationale, still all taking the course of its own aspect therapy and the medication rule, and formed more complete, unique theoretical system.Galla Turcica (Galla Helepensis) is regarded as treating the good medicine of various acute and chronic diseases associated with inflammation since ancient times in Uygur's medical science, have antiinflammatory, hemostasis, astringent or styptic treatment for spontaneous sweating, astringent effect, is used for the treatment of that periodontitis, dysentery are more than, habitual enteritis etc.The main component of Galla Turcica (Galla Helepensis) is a tannin, tannin claims tannin (tannin) again, be the polyhydric phenols that is present in a natural class formation more complicated, have effects such as convergence, antiinflammatory, antiallergic, antibacterial, antiviral, antitumor, hemostasis, analgesia, blood fat reducing, blood sugar lowering, enhancing renal function.Because tannin has more ortho position phenolic hydroxyl group, and is easily oxidized, therefore, be difficult to obtain monomer, also seldom both at home and abroad to the tannin The Chemical Constituents.
Ulcerative colitis is the not bright inflammatory bowel relevant with autoimmune of a kind of reason, with diarrhoea, mucosa pyemia, stomachache and tenesmus is cardinal symptom, is the digestive tract commonly encountered diseases and the difficult disease of pathological characteristic with mucous membrane of colon chronic inflammatory disease and ulcer.Discover that have contact between ulcerative colitis and colon cancer take place, thinking has part ulcerative colitis case finally can develop into colon cancer.The canceration of colitis depends mainly on occurrence degree, happening part and the course of disease length of colitis.Though clinical employing nonsteroidal anti-inflammatory drug treatment can reduce the canceration rate of colitis, but take for a long time, side effects of pharmaceutical drugs make patient be difficult to tolerance, and nonsteroidal anti-inflammatory drug has increased digestive tract ulcer and hemorrhage probability simultaneously, in the patient that the hemorrhage repeatedly and distal ileitis of intestinal is shown effect repeatedly, the use of such medicine is incompatible relatively.Therefore, seek new medicine, effectively control the development of colitis, and stop the canceration of colitis, be the focus that researcheres are paid close attention to always.
Discover that it is tumorigenic main mechanism that the abnormality proliferation of cell and differentiation are suppressed.The pair cell Study of apoptosis is found, the relatively stable dynamic equilibrium that is actually between cell proliferation, differentiation and the apoptosis of normal structure.The propagation of tumor cell, apoptosis not only are subjected to the influence of multiple factors such as medicine, lonizing radiation and approach, and some oncogene or tumor suppressor gene pair cell apoptosis also play important regulation.
The present invention is on the basis according to acquired " preventing and treating the oral-cavity cleaning liquor and the preparation method of oral pathology " (patent No. is ZL 97116074.0), develop the solid gum liquid of Galla Turcica (Galla Helepensis) (Xi Payi), and be put into for " Drug Standard of Ministry of Public Health of the Peoples Republic of China-Uigurs medicine fascicle " version in 1999 and record kind (numbering: 02CJ-15-02-13).The solid gum liquid of Galla Turcica (Galla Helepensis) (Xi Payi) is increased new indication by changing its route of administration, and the treatment that is used in the ulcer colon cancer in the mode of coloclysis has obtained good and clinical curative effect.
Studies show that the main component of the solid gum liquid of medicine Galla Turcica (Galla Helepensis) (Xi Payi) is a Galla halepensis extract, and is evident in efficacy to stomachache, diarrhoea and the pyemia etc. of chronic ulcerative colitis; Common pathogen to oral diseases such as staphylococcus aureus, beta hemolytic streptococcus, Diplococcus pneumoniaes has very strong inhibitory action; Obviously suppressing carrageenin induced mice pedal swelling and rat abdominal cavity leukocyte swims out of; Suppressing acetic acid induced mice capillary permeability increases; Suppress granuloma induced by implantation of cotton pellets; Rat temperature raises due to inhibition acetic acid induced mice writhing response and the yeast; Prolong the mice swimming time; Suppress the inductive mice delayed hypersensitivity of DNCB; Clotting time of mice is obviously shortened, prove that it all has remarkable inhibitory action to acute and chronic inflammatory reaction, and the effective permeability of inflammation-inhibiting stage blood capillary, alleviate and ooze out reaction, stronger antipyretic-antalgic and anti-fatigue effect are arranged simultaneously.
The present invention is directed to the solid gum liquid of medicine Galla Turcica (Galla Helepensis) by name in the clinical effectiveness of treatment ulcerative colitis and the internal relation between ulcerative colitis and the colon cancer generation, the application that main component Galla halepensis extract in the solid gum liquid of medicine Galla Turcica (Galla Helepensis) suppresses human colon cancer cell HT-29 propagation and induces its accent to die is set forth, increased the clinical scope of application of said preparation, for the control of colon cancer provides new natural drug.Do not find as yet that at home and abroad the solid gum liquid of Galla Turcica (Galla Helepensis) is applied to human body and suppresses HT-29 propagation and induce the report of its accent in dying.
Summary of the invention
The objective of the invention is to, the purposes of a kind of Galla halepensis extract in the medicine of preparation inhibition colon cancer cell HT-29 is provided, the present invention is on the basis of " preventing and treating the oral-cavity cleaning liquor and the preparation method of oral pathology " (patent No. is ZL 97116074.0), provides new purposes to the oral-cavity cleaning liquor of preventing and treating oral pathology.The present invention serves as the experiment carrier with human colon carcinoma HT-29 cell, adopt experimental techniques such as MTT, flow cytometry, set forth from cancer cell multiplication and apoptosis angle " prevent and treat oral pathology oral-cavity cleaning liquor " the main component Galla halepensis extract to the effect characteristics of human colon carcinoma HT-29 cell, by suppressing the mode of cell proliferation and cell death inducing, suppress the growth of colon cancer cell, this effect has concentration-effect dependency relationships.The resistive connection intestinal cancer site of action that has disclosed Galla halepensis extract from the molecular biology level is a novel targets, for the control of colon cancer provides new natural drug.
A kind of Galla halepensis extract of the present invention suppresses purposes in the medicine of colon cancer cell HT-29 in preparation, is to be 5 * 10 in concentration
4Add Galla halepensis extract in the exponential phase human colon carcinoma HT-29 cell suspension of individual/ml, its ultimate density is reached: 0.01ug/ul, 0.025ug/ul, 0.05ug/ul, 0.1ug/ul, 0.25ug/ul, 0.5ug/ul, 1.0ug/ul, 2.5ug/ul or 5ug/ul, at 5%CO
237 ℃ of temperature, common cultivation 3,6,12,24,48,72 hours, adopt the inhibitory action of MTT colorimetric method for determining Galla halepensis extract to human colon carcinoma HT-29 cell proliferation, the result proves that Galla halepensis extract can suppress human colon carcinoma HT-29 cell proliferation in the mode of time dependence and concentration dependent.
Described a kind of Galla halepensis extract suppresses purposes in the medicine of colon cancer cell HT-29 in preparation, is to be 5 * 10 in concentration
4Add Galla halepensis extract in the exponential phase human colon carcinoma HT-29 cell suspension of individual/ml, its ultimate density is reached: 0.1ug/ul, 0.25ug/ul, 0.5ug/ul, 1.0ug/ul or 2.5ug/ul, at 5%CO
2, 37 ℃ of temperature were cultivated 48,72 hours jointly, adopted flow cytometry to measure Galla halepensis extract to the apoptotic inducing action of colon cancer HT-29, and the result proves that Galla halepensis extract can be induced human colon carcinoma HT-29 apoptosis in the concentration dependent mode.
Galla halepensis extract of the present invention is with Galla Turcica (Galla Helepensis) medical material 20g, pulverizes, add water 200ml, soak after 1 hour, decocted 0.5 hour, decoct altogether 3 times, collecting decoction adopts the sheet frame method to filter, and adds 2g cyclamate, 1ml Herba Menthae essence and 0.5g sodium benzoate in the filtrate successively, stirring makes dissolving evenly, add water and make medicine liquid volume be adjusted to 1000ml, packing, sterilization get final product.
The specific embodiment
The technical scheme of the purposes of Galla halepensis extract of the present invention in the medicine of preparation inhibition colon cancer cell HT-29 is to realize by following approach:
1. experiment material
1.1 medicine and reagent
Prevent and treat oral-cavity cleaning liquor Qikanghabo Uygur Medicine Co., Ltd., Xinjiang of oral pathology
DMEM U.S. Gibeo company product
Biochemical and the RESEARCH ON CELL-BIOLOGY institute in human colon carcinoma HT-29 cell Shanghai
Hyclone Sijiqing Bioengineering Material Inst., Hangzhou City
The dehydrated alcohol Beijing Chemical Plant
MTT U.S. Amresco company product
Trypsin U.S. Sigma company product
1.2 key instrument
Superclean bench THEMOR
CO
2Incubator THEMOR
Dragon rises in electronic balance Shenyang
-20 ℃, 4 ℃ cryogenic refrigerator Siemens
Flow cytometer U.S. BECKMAN company product.
Cell counting count board Shanghai refinement company product.
Desk type high speed refrigerated centrifuger Beckman Coulter
TM, the U.S.
Inverted phase contrast microscope Japan OLMPUS
2. experimental technique
2.1 cell culture
Human colon cancer cell strain HT-29 grows in the DMEM culture medium that contains 10% hyclone, 37 ℃ of temperature, 5%CO
2Cultivate in the cell culture incubator of saturated humidity, changed culture fluid once in every 2-3 days, the cell of the trophophase of taking the logarithm is used for experiment.
2.2MTT method detects the effect that Galla halepensis extract suppresses human colon carcinoma HT-29 cell proliferation
(1) collect the logarithmic (log) phase cell, adjusting concentration of cell suspension is 5 * 10
4Individual/ml, every hole adds 100 μ l, bed board;
(2) 5%CO
2Temperature is hatched for 37 ℃, at the bottom of being paved with the hole to cell monolayer (96 hole flat underside), add Galla halepensis extract, the medicine ultimate density reaches: 0.01ug/ul, 0.025ug/ul, 0.05ug/ul, 0.1ug/ul, 0.25ug/ul, 0.5ug/ul, 1.0ug/ul, 2.5ug/ul or 5ug/ul, establish 4 multiple holes, the blank group is set simultaneously for every group;
(3) 5%CO
2, temperature is hatched for 37 ℃, continues to cultivate 3h, 6h, 12h, 24h, 48h and 72h, and every hole adds 20ulMTT solution (5mg/ml, i.e. 0.5%MTT), continues to cultivate 4h again;
(4) stop cultivating, the careful suction removed culture fluid in the hole;
(5) every hole adds 150 μ l dimethyl sulfoxide, put low-speed oscillation 10min on the shaking table, crystal is fully dissolved, measure the absorbance (A value) in each hole at enzyme-linked immunosorbent assay instrument OD490nm place, zeroing hole (culture medium, MTT, dimethyl sulfoxide) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide);
(6) experiment repeats 3 times;
(7) calculating of suppression ratio: suppression ratio=[(control group A value-blank group A value)-(experimental group A value-blank group A value)]/(control group A value-blank group A value) * 100%.The results are shown in Table 1
Table 1 Galla halepensis extract to the inhibitory action of human colon carcinoma HT-29 cell proliferation (
N=12)
Annotate: SPSS 13.0 statistical softwares, the repeated measure variance analysis, (different time sections) comparing difference has statistical significance (F=6.12, P＜0.05) in the group, and (negative control group and variable concentrations KJA) comparing difference has statistical significance (F=12.07 between group; P＜0.05).
The result: Galla halepensis extract is to the influence of human colon carcinoma HT-29 cell proliferation
This experiment acts on human colon carcinoma HT-29 cell with the variable concentrations Galla halepensis extract, cultivates 3h respectively, 6h, and 12h, 24h, 48h behind the 72h, observes the influence of medicine on cell proliferation.Draw following result (table 1) through MTT colorimetric method for determining and repeated measure variance analysis: prolong in time, same concentration Galla halepensis extract presents rising trend to human colon carcinoma HT-29 cell inhibiting rate, have time-the effect dependency relationships; The same time, with the increase of concentration, the inhibitory action of Galla halepensis extract on cell proliferation strengthens, and has concentration-effect dependency relationships.The two all shows: after Galla halepensis extract was intervened human colon carcinoma HT-29 cell, living cells quantity reduced, and cell proliferation is suppressed.
2.3 flow cytometer detects Galla halepensis extract and induces the colon cancer cell effect of apoptosis
(1) will be in the human colon carcinoma HT-29 cell of exponential phase, trypsinization, making cell concentration is 5 * 10
4Individual/the mL single cell suspension;
(2) above-mentioned cell suspension kind is gone into 10 culture bottles, the 5ml/ bottle, exponential phase to be entered makes drug level reach 0.1ug/ul, 0.25ug/ul, 0.5ug/ul, 1ug/ul or 2.5ug/ul, continues to cultivate 48h, and 72h establishes negative control group simultaneously;
(3) the cell culture fluid sucking-off to centrifuge tube, PBS washing attached cell once, with pancreatin cell dissociation buffer peptic cell;
(4) after cell dissociation gets off, add the cell culture fluid of collecting in the step (3), mixing is transferred in the centrifuge tube slightly, 1000rpm, and centrifugal 5 minutes, abandon supernatant, collecting cell with PBS re-suspended cell and counting gently, reaches 1 * 10
6Individual/mL;
(5) 3000rpm, centrifugal 2 minutes, abandon supernatant, collecting cell adds 400 μ LBanding Buffer re-suspended cells, adds 5 μ l Annexin V-FITC, puts upside down mixing cell suspension then back and forth, with it as for 4 ℃, lucifuge 15 minutes;
(6) add 10 μ l propidium iodide dyeing liquors, put upside down mixing cell suspension back and forth, 4 ℃ of lucifuges were placed 5 minutes;
(7) carrying out flow cytometer detects.
The apoptosis rate of table 248 hour Galla halepensis extract effect human colon carcinoma HT-29 cell (
N=3)
Annotate: △ represents to compare with matched group, and group difference has statistical significance (P＜0.05).
★ represents that KJA2.5ug/ul organizes and all the other each groups are compared, and group difference has statistical significance (P＜0.05).
The apoptosis rate of table 372 hour Galla halepensis extract effect human colon carcinoma HT-29 cell (
N=3)
Annotate: △ represents to compare with matched group, and group difference has statistical significance (P＜0.05).★ represents that KJA2.5ug/ul organizes and all the other each groups are compared, and group difference has statistical significance (P＜0.05).■ represents that KJA0.1ug/ul group compares with the 1.0ug/ul group, and difference has statistical significance (P＜0.05).
2.4 statistical procedures
Adopt the SPSS13.0 statistical software, usefulness mean scholar standard deviation (
) expression, adopt variance analysis.P＜0.05 expression difference has statistical significance.
The result: Galla halepensis extract is to the apoptotic influence of human colon carcinoma HT-29
Behind Galla halepensis extract effect human colon carcinoma HT-29 cell 48h and 72h, adopt Annexin V-FITC/PI double labelling, flow cytometry (FCM) is analyzed apoptotic cell, the result shows: Galla halepensis extract effect 48h, behind the 72h, the cell of early apoptosis and late period apoptotic cells all obviously more than negative control group (table 2,3): the same time period, with the increase of concentration, the Galla halepensis extract cell death inducing has concentration-effect dependency relationships; The isoconcentration Galla halepensis extract is at the effect not statistically significant of different time cell death inducing.
Conclusion:
The MTT experiment shows that Galla halepensis extract has certain propagation to colon cancer HT-29 cell to be suppressed and lethal effect, begins that from 0.5ug/ul colon cancer HT-29 cell is had tangible inhibited proliferation (P＜0.05).Along with Galla halepensis extract concentration increases, prolong action time gradually, and the survival rate of cell reduces gradually, and the inhibited proliferation that colon cancer HT-29 cell is subjected to obviously strengthens.Galla halepensis extract was handled colon cancer HT-29 cell after 72 hours, and the proliferation inhibition rate of colon cancer HT-29 cell has reached 88.35%.The result has shown that Galla halepensis extract has stronger inhibited proliferation to colon cancer HT-29 cell, and has time, dosage effect dependency.Experimental result shows, (5ug/ul) can significantly suppress the propagation of colon cancer HT-29 cell when Galla halepensis extract concentration was low, toxicity to normal cell and normal structure reduces greatly, the medicine that is expected to become a kind of safe and effective treatment ulcerative colitis and prevents its canceration.
The flow cytometer experiment shows, colon cancer HT-29 cell by Galla halepensis extract handle 48h, after 72 hours, dye through AnnexinV/PI pair, flow cytometer detects and shows: compare with negative control group, Galla halepensis extract processed group apoptosis rate obviously rises, have concentration-effect dependency, maximum apoptosis rate is 85.77 ± 7.03%, is about 10 times of negative control group.The result shows that Galla halepensis extract can significantly induce the people to tie the apoptosis of cancerous cell HT-29.
Show through test: Galla halepensis extract is by suppressing the purpose that human colon carcinoma HT-29 cell proliferation and cell death inducing reach treatment and prevention colon cancer.
Claims (2)
1. a Galla halepensis extract suppresses purposes in the medicine of colon cancer cell HT-29 in preparation, and it is characterized in that: in concentration is 5 * 10
4Add Galla halepensis extract in the exponential phase human colon carcinoma HT-29 cell suspension of individual/ml, its ultimate density is reached: 0.01ug/ul, 0.025ug/ul, 0.05ug/ul, 0.1ug/ul, 0.25ug/ul, 0.5ug/ul, 1.0ug/ul, 2.5ug/ul or 5ug/ul, at 5%CO
2, 37 ℃ of temperature cultivate 3,6,12,24 jointly, 48,72 hours, adopt the inhibitory action of MTT colorimetric method for determining Galla halepensis extract to human colon carcinoma HT-29 cell proliferation.
2. a Galla halepensis extract suppresses purposes in the medicine of colon cancer cell HT-29 in preparation, and it is characterized in that: in concentration is 5 * 10
4Add Galla halepensis extract in the exponential phase human colon carcinoma HT-29 cell suspension of individual/ml, its ultimate density is reached: 0.1ug/ul, 0.25ug/ul, 0.5ug/ul, 1.0ug/ul or 2.5ug/ul, at 5%CO
2, 37 ℃ of temperature were cultivated 48,72 hours jointly, adopted flow cytometry to measure Galla halepensis extract to the apoptotic inducing action of colon cancer HT-29.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105680272A CN102000117B (en) | 2010-12-01 | 2010-12-01 | Use of nutgall extract in preparing medicine for inhibiting cell proliferation of colon cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105680272A CN102000117B (en) | 2010-12-01 | 2010-12-01 | Use of nutgall extract in preparing medicine for inhibiting cell proliferation of colon cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102000117A true CN102000117A (en) | 2011-04-06 |
| CN102000117B CN102000117B (en) | 2013-03-13 |
Family
ID=43807985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105680272A Expired - Fee Related CN102000117B (en) | 2010-12-01 | 2010-12-01 | Use of nutgall extract in preparing medicine for inhibiting cell proliferation of colon cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102000117B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152192A (en) * | 2007-09-28 | 2008-04-02 | 南方医科大学 | Application of 1,3-2-O-gallnut acyl 1-4,6-(S)-HHDP-beta-D-glucopyranose in preparing antineoplastic medicament |
| CN101862351A (en) * | 2010-06-30 | 2010-10-20 | 斯拉甫·艾白 | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine |
-
2010
- 2010-12-01 CN CN2010105680272A patent/CN102000117B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152192A (en) * | 2007-09-28 | 2008-04-02 | 南方医科大学 | Application of 1,3-2-O-gallnut acyl 1-4,6-(S)-HHDP-beta-D-glucopyranose in preparing antineoplastic medicament |
| CN101862351A (en) * | 2010-06-30 | 2010-10-20 | 斯拉甫·艾白 | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102000117B (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100387145C (en) | Gingko tea preparation and production process thereof | |
| CN102114044B (en) | Artificially processed bear bile powder and preparation method thereof | |
| CN100453094C (en) | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method | |
| CN102178804B (en) | Chinese medicinal composition for treating perianal eczema and preparation method thereof | |
| CN102743741A (en) | Preparation of blattodea polypeptide, and uses of the same in anti-gram-positive bacteria and anti-gram-negative bacteria | |
| CN105504076B (en) | A kind of radix tetrastigme root tuber polysaccharide acted on antipyretic and anti-inflammatory and application thereof | |
| CN105017438B (en) | A kind of Radix et Rhizoma Gynurae divaricatae polysaccharide and its application in preparing for immunological regulation and anti-tumor drug and functional food | |
| CN108272915A (en) | A kind of pharmaceutical composition and its preparation and purposes | |
| CN102085248B (en) | Traditional Chinese medicinal composition for treating cervix diseases, method for preparing same and method for detecting same | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN105687036A (en) | Rhizoma bletillae skin care product and method for preparing same | |
| CN104605345A (en) | Healthcare food containing lactobacillus paracasei for treatment of hyperlipidemia | |
| CN101168008B (en) | Medicinal composition with tumor inhibition function and preparation method and application thereof | |
| CN102000117B (en) | Use of nutgall extract in preparing medicine for inhibiting cell proliferation of colon cancer | |
| CN108096528B (en) | Traditional Chinese medicine composition for enhancing sensitivity of esophageal cancer to chemotherapeutic drugs and application thereof | |
| CN101947297A (en) | Chinese medicinal composition for treating senile pneumonia, decoction-free granules and preparation method thereof | |
| CN1322874C (en) | Medicine contg. zinc, honeysuckle, Radix scutellariae and forsynthia fruit | |
| CN101028311B (en) | Use of selaginella tamariscina | |
| CN100462094C (en) | Chinese-medicinal preparation for treating urinary system disease | |
| CN105708845B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| CN103610849A (en) | Application of renqingchangjue (Chinese character) in preparation of drug for treating prostatic cancer | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN102068537B (en) | The preparation of Pericarpium Citri Reticulatae Radix Glycyrrhizae prevents and treats the health food of nasopharyngeal carcinoma and the production method of medicine | |
| CN102247352A (en) | Method for preparing sodium quercetin-7-sulfate and application of sodium quercetin-7-sulfate to preparation of medicaments and health-care products for resisting thrombus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 Termination date: 20171201 |